Results 71 to 80 of about 10,001 (276)
Combination octreotide, midodrine, and albumin may improve survival in patients with Hepatorenal syndrome, but the evidence is weak [PDF]
, 2017 A critical appraisal and clinical application of Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol.
Szafranski, Jacob
core +2 more sources
Egyptian Journal of Anaesthesia, 2023 Background and Aims Liver transplantation is associated with hemodynamic instability. Systemic and Splanchnic circulations interact closely. Portal hypertension is linked to vasodilatory molecules resulting in arterial vasodilatation.
R. M. Hashim +4 more
semanticscholar +1 more source
Role of RIPK1/RIPK3/MLKL signalling pathway in sepsis‐associated acute kidney injury
Experimental Physiology, EarlyView.Abstract Sepsis‐associated acute kidney injury (SA‐AKI) is a common clinical syndrome in critically ill patients, and its high mortality rate is closely related to complex pathological mechanisms. Existing studies have shown that the pathophysiological process of SA‐AKI involves complex multi‐mechanism interactions, including an uncontrolled systemic ...
Huijun Yin, Jingyi Wang, Huirong Han
wiley +1 more source
Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe hepatic encephalopathy [PDF]
, 2004 There is increasing evidence that terlipressin is useful in patients with cirrhosis and hepatorenal syndrome, but there are no data of its use in patients with acute liver failure (ALF) in whom hepatorenal syndrome is common.
Davies, N.A. +6 more
core
The course of type 1 hepato-renal syndrome post liver transplantation [PDF]
, 2005 Background. Hepato-renal syndrome (HRS) is a functional form of renal failure that occurs in patients with end-stage liver disease. Previously considered fatal without liver transplantation, treatment with vasoconstrictors and albumin has been ...
Marik, PE, Starzl, TE, Wood, K
core +1 more source
Advances in Therapy, 2023 Introduction Hepatorenal syndrome (HRS), a special form of acute kidney failure, is a rare, acute, life-threatening complication of cirrhosis and has a very poor prognosis. Terlipressin (TERLIVAZ®) is the first and only pharmacological treatment approved
Xingyue Huang +4 more
semanticscholar +1 more source
Management Strategies for Refractory Esophageal Varices
DEN Open, Volume 6, Issue 1, April 2026.ABSTRACT Refractory esophageal varices that are difficult to control or unresponsive to endoscopic treatment remain a major clinical challenge in the management of portal hypertension. This review provides a comprehensive overview of treatment strategies for these cases, along with a comparative analysis of the American Association for the Study of ...
Keita Maki, Hiroaki Haga, Yoshiyuki Ueno
wiley +1 more source
Cutaneous Ischaemia Following Terlipressin Therapy for Hepatorenal Syndrome [PDF]
Journal of Clinical and Diagnostic Research, 2018 Hepatorenal Syndrome (HRS) is a potentially fatal complication of hepatic failure and portal hypertension. Among the various treatments available including octreotide, midodrine and albumin, the current standard of care for stable patients is ...
Aneesh Basheer +3 more
doaj +1 more source
TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update [PDF]
, 2010 Refractory ascites is a frequent complication of advanced cirrhosis and is associated with hepatorenal syndrome and hepatic hydrothorax. Large volume paracentesis and pleurodesis are regarded as first-line treatments in patients who do not respond ...
Gerbes, Alexander L., Roessle, Martin
core +1 more source
The FASEB Journal, Volume 39, Issue 17, 15 September 2025.The study involved patients who experienced acute kidney injury (AKI) following liver transplantation at the Third Affiliated Hospital of Sun Yat‐sen University from January 2015 to February 2023. Patients were categorized into CKD and non‐CKD groups based on their progression to chronic kidney disease (CKD) 3 months post‐surgery.
Liping Li +9 more
wiley +1 more source